Eli Lilly And Co vs Global X Robo Global Robotics & Automation ETF — how do they compare? Eli Lilly And Co trades at $1,220.21 (market cap $1.08T), while Global X Robo Global Robotics & Automation ETF trades at $84.75. The key difference: Eli Lilly And Co pays a 0.57% dividend while Global X Robo Global Robotics & Automation ETF pays none. Which is the better fit depends on your goals.
| LLY | ROBO | |
|---|---|---|
Market Cap | $1.08T | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.24K | $90.34 |
52-Week Low | $639.43 | $62.34 |
Enterprise Value | $1.13T | — |
Dividend Yield | 0.57% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
ROBO Global Robotics and Automation Index ETF (ROBO) trades at $84.79, up 1.59% with strong bullish technical signals from moving averages. The robotics ETF benefits from AI infrastructure expansion and recent sector momentum, though key valuation metrics remain undisclosed. Recent news highlights robotics as the next phase of AI investment beyond semiconductors, with thematic ETF comparisons favoring ROBO's diversified approach to automation exposure.
Outlook remains positive given structural AI adoption tailwinds, but elevated RSI levels suggest near-term consolidation risk. The ETF's 79-stock global portfolio offers diversified robotics exposure, though cyclical industrial dependencies and valuation concerns after recent rallies present balanced risk-reward dynamics for long-term investors.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →